PTCT · Ptc Therapeutics, Inc. · Webcasts, Transcripts & Audio
$63.49
+0.13 (+0.21%)
At close · Nov 13
View the 10-K filed Feb 19, 2026
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Customer concentration
— top 4 customers 10% of revenue
4 customers — 10% of revenue (2025)
“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
Market Cap
$5.30B
Shares
83.54M
Volume · Nov 13
502.9K
Avg daily vol (3M)
1.07M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ptc Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Ptc Therapeutics, Inc. (PTCT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-01
Ptc Therapeutics, Inc. (PTCT) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
Ptc Therapeutics, Inc. (PTCT) November 16, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-29
Ptc Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
Confident tone
Suffiance launch momentum and expansion
International launches and reimbursement
U.S. market opportunity and patient switching
Revenue
$357.81M
▲ 69.6% YoY Diluted EPS
$-0.62
▼ 410% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Ptc Therapeutics, Inc. (PTCT) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-10
Ptc Therapeutics, Inc. (PTCT) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Ptc Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript
Confident tone
Suffiance/Duchenne launch momentum
PTC-303 splicing/HD program
Switching dynamics and real-world data
Revenue
$360.52M
▲ 101.5% YoY Diluted EPS
$0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Ptc Therapeutics, Inc. (PTCT) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-20
Ptc Therapeutics, Inc. (PTCT) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Ptc Therapeutics, Inc. (PTCT) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-28
Ptc Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
Confident tone
Seysara (suffiance) global launch momentum
International expansion and Japan launch
2026 financial guidance raise
Revenue
$272.55M
▼ 76.8% YoY Diluted EPS
$-0.03
▼ 100.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
Ptc Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript
Confident tone
Sephience (sepiapterin) launch
Vatiquinone regulatory path
Huntington's disease program (votoplam)
Revenue
$164.68M*
▼ 22.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-12-02
Ptc Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript
Confident tone
Sephience global launch
International expansion
DMD franchise and revenue
Revenue
$211.01M
▲ 7.2% YoY Diluted EPS
$0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ptc Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript
Confident tone
Sephience (PKU) launch
Duchenne muscular dystrophy (DMD) franchise
Vatiquinone Friedreich's ataxia NDA review
Revenue
$178.88M
▼ 4.2% YoY Diluted EPS
$-0.83
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Ptc Therapeutics, Inc. (PTCT) Q1 2025 Earnings Call Transcript
Confident tone
SUFIANCE launch and regulatory progress
Revenue performance and guidance
DMD franchise (Translarna and Emflaza)
Revenue
$1.18B
▲ 459.7% YoY Diluted EPS
$10.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Ptc Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript
Confident tone
Commercial performance and revenue
Sepiapterin global launch (PKU)
PTC518 Huntington's disease program
Revenue
$213.17M*
▼ 30.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Ptc Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
Positive tone
Sepiapterin for PKU
Utreloxastat (CardinALS) for ALS
Vatiquinone for Friedreich ataxia
Revenue
$196.79M
▲ 0.1% YoY Diluted EPS
$-1.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ptc Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript
Confident tone
Sepiapterin PKU launch preparation
Commercial revenue and guidance
Utreloxastat ALS
Revenue
$186.70M
▼ 12.7% YoY Diluted EPS
$-1.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Ptc Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript
Confident tone
DMD franchise (Translarna/Emflaza) revenue
Sepiapterin for PKU global launch
Utreloxastat / CardinALS in ALS
Revenue
$210.12M
▼ 4.7% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Ptc Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
Confident tone
Sepiapterin for PKU regulatory progress
Utreloxastat CARDINAL trial in ALS
Vatiquinone for Friedreich ataxia NDA path
Revenue
$307.06M*
▲ 83.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Ptc Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript
Revenue
$196.58M
▼ 9.5% YoY Diluted EPS
$-1.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Ptc Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript
Revenue
$213.81M
▲ 29.2% YoY Diluted EPS
$-2.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Ptc Therapeutics, Inc. (PTCT) Q1 2023 Earnings Call Transcript
Revenue
$220.38M
▲ 48.2% YoY Diluted EPS
$-1.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Ptc Therapeutics, Inc. (PTCT) Q4 2022 Earnings Call Transcript
Revenue
$167.41M*
▲ 1.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Ptc Therapeutics, Inc. (PTCT) Q3 2022 Earnings Call Transcript
Revenue
$217.13M
▲ 56.5% YoY Diluted EPS
$-1.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ptc Therapeutics, Inc. (PTCT) Q2 2022 Earnings Call Transcript
Revenue
$165.53M
▲ 41.9% YoY Diluted EPS
$-2.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Ptc Therapeutics, Inc. (PTCT) Q1 2022 Earnings Call Transcript
Revenue
$148.74M
▲ 26.1% YoY Diluted EPS
$-1.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Ptc Therapeutics, Inc. (PTCT) Q4 2021 Earnings Call Transcript
Revenue
$165.23M*
▲ 39% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Ptc Therapeutics, Inc. (PTCT) Q3 2021 Earnings Call Transcript
Revenue
$138.74M
▲ 17.2% YoY Diluted EPS
$-1.89
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Ptc Therapeutics, Inc. (PTCT) Q2 2021 Earnings Call Transcript
Revenue
$116.68M
▲ 55.1% YoY Diluted EPS
$-1.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Ptc Therapeutics, Inc. (PTCT) Q1 2021 Earnings Call Transcript
Revenue
$117.94M
▲ 72.8% YoY Diluted EPS
$-1.83
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Ptc Therapeutics, Inc. (PTCT) Q4 2020 Earnings Call Transcript
Revenue
$118.86M*
▲ 23.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Ptc Therapeutics, Inc. (PTCT) Q3 2020 Earnings Call Transcript
Revenue
$118.40M
▲ 65.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Ptc Therapeutics, Inc. (PTCT) Q2 2020 Earnings Call Transcript
Revenue
$75.24M
▼ 12% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Ptc Therapeutics, Inc. (PTCT) Q1 2020 Earnings Call Transcript
Revenue
$68.26M
▲ 27.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Ptc Therapeutics, Inc. (PTCT) Q4 2019 Earnings Call
Revenue
$96.46M*
▲ 12.4% YoY Gross margin
96.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–35 of 35 webcasts
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
284 filings
256 filers
Visit website
Investor relations